Orphan Drug Designation Provided to a Treatment for Chronic Inflammatory Demyelinating Polyneuropathy
source: pixabay.com

Orphan Drug Designation Provided to a Treatment for Chronic Inflammatory Demyelinating Polyneuropathy

The FDA has just provided Orphan Drug Designation to Hizentra for the treatment of adults diagnosed with chronic inflammatory demyelinating polyneuropathy (CIPD). This is a maintenance therapy which works to…

Continue Reading Orphan Drug Designation Provided to a Treatment for Chronic Inflammatory Demyelinating Polyneuropathy

Webinar: CIDP Patient Speaker Program

Speakers: Elizabeth Thirtyacre Carla Duff, ANP To register for this webinar, click here. To read more about Webinar Wednesdays, click here.    Acknowledgment: This event post is sponsored by CSL Behring and is…

Continue Reading Webinar: CIDP Patient Speaker Program

Webinar: CIDP Patient Speaker Program

Speakers: Danielle Ball Lisa Mandolfo, MSN To register for this webinar, click here. To read more about Webinar Wednesdays, click here.    Acknowledgment: This event post is sponsored by CSL Behring and is…

Continue Reading Webinar: CIDP Patient Speaker Program
Close Menu